News

Insmed: Company Presses On With Further POC PAH Treatment Data
Insmed achieved positive phase 2b results for TPIP in PAH. Click here to find out why INSM stock is a Strong Buy.
Target: Something Has To Change
Target is currently undervalued, trading at a significant discount to its historical averages and peers. Click here to read ...